Gene: C17orf100
Official Full Name: chromosome 17 open reading frame 100provided by HGNC
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO19152 | C17orf100 Knockout cell line (HeLa) | Human | C17orf100 | 1:3~1:6 | Negative | Online Inquiry |
KO19153 | C17orf100 Knockout cell line (HCT 116) | Human | C17orf100 | 1:2~1:4 | Negative | Online Inquiry |
KO19154 | C17orf100 Knockout cell line (HEK293) | Human | C17orf100 | 1:3~1:6 | Negative | Online Inquiry |
KO19155 | C17orf100 Knockout cell line (A549) | Human | C17orf100 | 1:3~1:4 | Negative | Online Inquiry |
C17orf100 Gene Knockout Cell Lines are specialized cellular models designed for the precise study of the C17orf100 gene function through the complete inactivation of its expression. This gene, known for its involvement in several cellular processes, remains poorly understood; however, its modulation can significant impacts on cellular signaling pathways, allowing researchers to define its role in health and disease.
These cell lines function through various mechanisms, including the application of CRISPR/Cas9 gene-editing technology, allowing for targeted deletion of the C17orf100 gene. By creating knockout models, researchers can investigate the phenotypic consequences of gene loss, offering insights into cellular behavior, gene-drug interactions, and the gene's potential impact on pathological conditions. This functional analysis is critical in validating the gene's role in disease mechanisms, making these cell lines invaluable in both basic and applied research.
The scientific importance of C17orf100 Gene Knockout Cell Lines is evident in their versatility for use in various research applications, including cancer biology, developmental studies, and pharmacogenomics. Their use in preclinical studies enables researchers to assess the therapeutic potential of new drugs, providing a platform to screen for effective interventions targeting pathways associated with C17orf100 expression.
Compared to alternative models, our C17orf100 Gene Knockout Cell Lines offer high specificity, consistent reproducibility, and user-friendly validation processes. Unlike traditional methods of gene knockdown, which can result in residual gene activity, our knockout models ensure complete gene ablation, providing robust experimental controls. This ensures reliable data generation that empowers researchers, reducing the time and resources needed for accurate results.
For researchers, clinicians, and pharmaceutical industries seeking to investigate the roles of genes in disease, C17orf100 Gene Knockout Cell Lines represent a crucial tool that bridges basic science with translational medicine. Our company, with its extensive experience in gene-editing technologies and commitment to advancing biological research, offers these high-quality cell lines to facilitate groundbreaking discoveries and improve patient outcomes.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.